Monitoring during hepatitis C treatment

Direct-acting antiviral drugs are generally well tolerated and most patients do not require monitoring during treatment. Arrange follow-up on a case-by-case basis; for example, if it is necessary to monitor adherence or provide social support, or if there is concern about adverse effects or drug interactions. Advise patients to contact their treating clinician if problems arise during treatment.

Patients with decompensated liver disease or comorbidities requiring specialist care often need more frequent assessment during treatment.